Trevi Therapeutics, Inc. (TRVI) Stock
3 of the hedge funds AlphaScala tracks reported TRVI in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $49.87M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own TRVI?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 2.67M | $49.87M | -33% |
| Viking Global Investors Andreas Halvorsen | 1.54M | $28.81M | -52% |
| D.E. Shaw David Shaw | 282K | $5.26M | +56% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Trevi Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 15, 26 | Heffernan Michael Thomas | Director | SELL | 18.3K | $276K |
| Sep 15, 26 | Heffernan Michael Thomas | Director | SELL | 100 | $2K |
| Sep 15, 26 | Heffernan Michael Thomas | Director | SELL | 21.0K | $316K |
| Sep 15, 26 | Heffernan Michael Thomas | Director | SELL | 100 | $2K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →TRVI price chart
Powered by TradingViewWhat does Trevi Therapeutics, Inc. do?
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an oral extended-release formulation of nalbuphine, for treating chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Haduvio acts as a kappa opioid receptor agonist and mu opioid receptor antagonist, targeting the cough reflex arc both centrally and peripherally to address nerve hypersensitivity underlying these conditions, where no approved therapies exist in the U.S. The company is advancing Haduvio through late-stage clinical trials, including positive Phase 2b results demonstrating statistically significant reductions in cough frequency. Trevi Therapeutics Inc. operates in the biotechnology sector, concentrating on neurologically mediated cardiorespiratory diseases that impose substantial burdens on patients, caregivers, and healthcare systems. Founded in 2011 and headquartered in New Haven, Connecticut, the company leverages its expertise in opioid receptor modulation to deliver novel investigational therapies for unmet medical needs in chronic cough management.